Dr. Xiaozhen (Shawn) Yu

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

Cooley advised Earendil Labs, an artificial intelligence-driven biotech company affiliated with Helixon Therapeutics, in connection with Earendil Labs’ license agreement with Sanofi for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases.

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Cooley advised the underwriters in LumiraDx Limited’s $100.3 million aggregate financing, consisting of (1) a $75.3 million follow-on offering of 43,000,000 shares of common stock at a public offering price of $1.75 per share and (2) a $25.0 million concurrent private placement with the Bill & Melinda Gates Foundation. LumiraDx is a diagnostics company manufacturing and commercializing an innovative diagnostic platform that supports a broad menu of tests with lab-comparable performance at the point of care. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Cooley advised the underwriters on SOPHiA Genetics’ $234 million initial public offering of 13,000,000 ordinary shares. J.P. Morgan Securities LLC, Morgan Stanley & Co., Cowen and Company, LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. SOPHiA Genetics, whose securities now trade on the Nasdaq Global Select Market under the symbol “SOPH,” is the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine. Partners Richard Segal, Div Gupta and Eric Blanchard led the Cooley team.